XNCR vs. KURA, ZYME, MGNX, PRLD, AIMT, APLS, RNA, ALKS, CRNX, and AXSM
Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Kura Oncology (KURA), Zymeworks (ZYME), MacroGenics (MGNX), Prelude Therapeutics (PRLD), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Alkermes (ALKS), Crinetics Pharmaceuticals (CRNX), and Axsome Therapeutics (AXSM). These companies are all part of the "medical" sector.
Xencor (NASDAQ:XNCR) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.
Xencor received 91 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 73.05% of users gave Xencor an outperform vote while only 69.11% of users gave Kura Oncology an outperform vote.
Xencor presently has a consensus target price of $35.38, suggesting a potential upside of 63.39%. Kura Oncology has a consensus target price of $31.33, suggesting a potential upside of 48.57%. Given Xencor's higher possible upside, equities research analysts clearly believe Xencor is more favorable than Kura Oncology.
In the previous week, Xencor and Xencor both had 3 articles in the media. Kura Oncology's average media sentiment score of 1.24 beat Xencor's score of 1.11 indicating that Kura Oncology is being referred to more favorably in the news media.
Kura Oncology has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Kura Oncology's return on equity.
Xencor has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Xencor has higher revenue and earnings than Kura Oncology. Xencor is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Xencor beats Kura Oncology on 8 of the 13 factors compared between the two stocks.
Get Xencor News Delivered to You Automatically
Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
